Abiraterone inhibits 1α,25-dihydroxyvitamin D3 metabolism by CYP3A4 in human liver and intestine in vitro
- 1 October 2014
- journal article
- review article
- Published by Elsevier BV in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 144, 50-58
- https://doi.org/10.1016/j.jsbmb.2013.10.027
Abstract
No abstract availableKeywords
Funding Information
- Motorcycle Ride for Dad
- Sanofi Aventis
This publication has 48 references indexed in Scilit:
- Vitamin D dose response is underestimated by Endocrine Society's Clinical Practice GuidelineEndocrine Connections, 2013
- Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 studyThe Lancet Oncology, 2012
- Dietary Vitamin D3 and 1,25-Dihydroxyvitamin D3 (Calcitriol) Exhibit Equivalent Anticancer Activity in Mouse Xenograft Models of Breast and Prostate CancerEndocrinology, 2012
- Potent mechanism‐based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substratesBritish Journal of Pharmacology, 2011
- Comorbidity and Mortality Results From a Randomized Prostate Cancer Screening TrialJournal of Clinical Oncology, 2011
- CYP24A1 Inhibition Enhances the Antitumor Activity of CalcitriolEndocrinology, 2010
- Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole TherapyJournal of Clinical Oncology, 2010
- Vitamin D deficiency and insufficiency among patients with prostate cancerBJU International, 2009
- Association between serum 25(OH)D and death from prostate cancerBritish Journal of Cancer, 2009
- Vitamin D signalling pathways in cancer: potential for anticancer therapeuticsNature Reviews Cancer, 2007